{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14"}]}],"title":"Thrombosis/embolism (vascular access-related)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"100"}]}],"title":"Platelets"},{"categories":[{"measurements":[{"groupId":"OG000","value":"100"}]}],"title":"Neutrophils/granulocytes (ANC/AGC)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"57"}]}],"title":"Lymphopenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"100"}]}],"title":"Leukocytes (total WBC)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14"}]}],"title":"Infection with unknown ANC - Upper airway NOS"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14"}]}],"title":"Infection with normal ANC or Grade 1 or 2 neutroph"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14"}]}],"title":"Infection with unknown ANC - Bladder (urinary)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"28"}]}],"title":"Infection"},{"categories":[{"measurements":[{"groupId":"OG000","value":"28"}]}],"title":"Infection Grade 3 or 4 neutrophils-blood"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14"}]}],"title":"Hemorrhage, GI (lower GI NOS/Rectum)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14"}]}],"title":"Hemorrhage/Bleeding - Other"},{"categories":[{"measurements":[{"groupId":"OG000","value":"100"}]}],"title":"Hemoglobin"},{"categories":[{"measurements":[{"groupId":"OG000","value":"28"}]}],"title":"Fever (in the absence of neutropenia)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14"}]}],"title":"Febrile neutropenia (fever of unknown origin)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"description":"All patients who received study drug were closely monitored for adverse events (AEs). All AEs that occured during study period were reported and the investigator determined the severity and relationship to study drug (unrelated, unlikely, possibly, probably, or definitely related). The NCI's CTCAE(Common Toxicity Criteria for Adverse Effects)v3.0 was used for grading AEs.","groups":[{"description":"Cycle 1- 5-azacytidine (Vidaza, AZA) 75mg/m2 IV/SC daily on days 1-7.\n\nSubsequent Cycles (cycles to be repeated every 28 days) AZA 75mg/m2 IV/SC daily on days 1-7.","id":"OG000","title":"5-azacytidine and Lintuzumab"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"up to 5 years","title":"Toxicities of the Combination","type":"SECONDARY","unitOfMeasure":"percentage of participants"}